ECSP066595A - Anticuerpo del receptor anti-igf-i - Google Patents

Anticuerpo del receptor anti-igf-i

Info

Publication number
ECSP066595A
ECSP066595A EC2006006595A ECSP066595A ECSP066595A EC SP066595 A ECSP066595 A EC SP066595A EC 2006006595 A EC2006006595 A EC 2006006595A EC SP066595 A ECSP066595 A EC SP066595A EC SP066595 A ECSP066595 A EC SP066595A
Authority
EC
Ecuador
Prior art keywords
antibodies
igf
cancer
receptor
elevated levels
Prior art date
Application number
EC2006006595A
Other languages
English (en)
Inventor
Daniel Tavares
Rajeeva Singh
Nancy E Dagdigian
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/729,441 external-priority patent/US8034904B2/en
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of ECSP066595A publication Critical patent/ECSP066595A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

Los anticuerpos, anticuerpos humanizados, anticuerpos recubiertos, fragmentos de anticuerpo, anticuerpos derivatizados y conjugados de los mismos con agentes citotóxicos, que específicamente se enlazan a, e inhiben al receptor del factor I de crecimiento de tipo insulina, antagonizan los efectos de IGF-I, IGF-II y suero en el crecimiento y supervivencia de células de tumor, y que substancialmente carecen de actividad agonista. Los anticuerpos y fragmentos de los mismos por consiguiente se pueden utilizar, opcionalmente en conjunción con otros agente terapéuticos, en el tratamiento de tumores que expresan niveles elevados del receptor IGF-I, tales como cáncer de pecho, cáncer de colon, cáncer de pulmón, sarcoma sinovial, cáncer de próstata, y cáncer pancreático, y los anticuerpos derivatizados se pueden utilizar en el diagnóstico y formación de imágenes de tumores que expresan niveles elevados del IGF-I.
EC2006006595A 2003-12-08 2006-05-31 Anticuerpo del receptor anti-igf-i ECSP066595A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/729,441 US8034904B2 (en) 2002-06-14 2003-12-08 Anti-IGF-I receptor antibody

Publications (1)

Publication Number Publication Date
ECSP066595A true ECSP066595A (es) 2006-10-17

Family

ID=36616549

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006595A ECSP066595A (es) 2003-12-08 2006-05-31 Anticuerpo del receptor anti-igf-i

Country Status (13)

Country Link
EP (1) EP1692176A4 (es)
JP (1) JP2008502589A (es)
KR (1) KR20070001883A (es)
CN (1) CN1886424A (es)
AU (1) AU2004303792A1 (es)
BR (1) BRPI0417406A (es)
CA (1) CA2548065A1 (es)
CR (1) CR8426A (es)
EA (1) EA009807B1 (es)
EC (1) ECSP066595A (es)
IL (1) IL174770A0 (es)
MX (1) MXPA06005540A (es)
NO (1) NO20063155L (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG181834A1 (en) 2009-12-21 2012-07-30 Genentech Inc Antibody formulation
KR20130065665A (ko) * 2010-05-11 2013-06-19 아베오 파마슈티컬즈, 인크. 항-fgfr2 항체
EP2766478A4 (en) 2011-10-10 2015-06-17 Los Angeles Childrens Hospital NEW ASPARAGINASE AND METHOD FOR THE TREATMENT OF DISEASES RELATED TO ASPARAGINE DEPENDENCE
CN103509117B (zh) * 2013-05-06 2016-03-09 江苏匡亚生物医药科技有限公司 抗人her2和人igf-ir的双特异性抗体及其制备方法和用途
CN110691794B (zh) * 2017-05-30 2023-10-27 帝人制药株式会社 抗igf-i受体抗体
CN118615438A (zh) * 2023-03-07 2024-09-10 康方药业有限公司 包含抗ctla4-抗pd-1双特异性抗体的药物组合及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2351452A1 (en) * 1998-12-04 2000-06-15 Novartis Ag Methods and compositions useful for targeting activated vitronectin receptor .alpha.v.beta.3
EP2796468A2 (en) * 2001-01-05 2014-10-29 Pfizer Inc Antibodies to insulin-like growth factor I receptor
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
CA2514231A1 (en) * 2003-02-13 2004-08-26 Pfizer Products Inc. Uses of anti-insulin-like growth factor i receptor antibodies

Also Published As

Publication number Publication date
IL174770A0 (en) 2006-08-20
EP1692176A4 (en) 2008-11-12
EP1692176A1 (en) 2006-08-23
JP2008502589A (ja) 2008-01-31
CA2548065A1 (en) 2005-07-07
MXPA06005540A (es) 2006-08-17
EA200600931A1 (ru) 2006-10-27
AU2004303792A1 (en) 2005-07-07
CR8426A (es) 2007-12-04
EA009807B1 (ru) 2008-04-28
BRPI0417406A (pt) 2007-04-03
NO20063155L (no) 2006-08-11
KR20070001883A (ko) 2007-01-04
CN1886424A (zh) 2006-12-27

Similar Documents

Publication Publication Date Title
SG141243A1 (en) Anti-igf-i receptor antibody
AR061911A1 (es) Anticuerpo antagonista para el tratamiento del cancer
CL2017001580A1 (es) Anticuerpo o fragmento de anticuerpo contra cd38 anticuerpo humanizado, conjugado del anticuerpo con un compuesto citotoxico composición farmacéutica con dichos anticuerpos uso de los anticuerpos para tratar cáncer o enfermedad autoinmune método para diagnosticar cáncer polinucleotido vector y célula huésped.
PE20080663A1 (es) Terapia tumoral con una combinacion de anticuerpos anti-her2
UA94388C2 (ru) Антиинтегриновый иммуноконьюгат и способы лечения с его помощью
NO20070945L (no) Induksjon av apoptose i tumorceller som uttrykker toll-lignende reseptor
AR061245A1 (es) Composiciones y metodos para la modulacion del desarrollo vascular
CU20130130A7 (es) Anticuerpos tipo receptor de células t específicos para un péptido wt1 presentado por hla-a2
AR074360A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
DOP2013000045A (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
AR054175A1 (es) Nuevos anticuerpos anti-igf-ir y usos de los mismos
WO2006138729A3 (en) Receptor antagonists for treatment of metastatic bone cancer
MX2010005081A (es) Metodo para determinar la probabilidad de una respuesta terapeutica en la quimioterapia para el cancer con un glicosido cardiaco.
UA99608C2 (en) PDGFRb-SPECIFIC INHIBITORS
EA032908B1 (ru) Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 158p1d7
NZ599707A (en) Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
WO2007100640A3 (en) Growth hormone receptor antagonist cancer treatment
EA202193309A1 (ru) Конъюгаты антитело к тканевому фактору-лекарственное средство и связанные способы
WO2021048564A3 (en) Antigen-binding domain
ECSP066595A (es) Anticuerpo del receptor anti-igf-i
CO6331345A2 (es) Composiciones y métodos que proporcionan una línea celular de hibridoma depositada como no. de acceso atcc pta-9387 y un anticuerpo producido por esta línea celular de hibridoma
PE20130460A1 (es) Composiciones y metodos para el diagnostico y tratamiento de tumores
EA200601405A1 (ru) Гуманизированное антитело
AR078667A1 (es) Moduladores de activador del factor de crecimiento de hepatocitos (hgfa)
DOP2009000003A (es) Anticuerpo antagonista para el tratamiento del cancer